How to Screen Monoclonal-Antibody FTO Risk by Claim Layer
Monoclonal-antibody FTO is not one keyword search. It separates sequence and product claims from formulation, manufacturing, use, regimen, and pending-claim layers, then maps each material claim to the exact candidate version and planned acts.
This partial public-asset run uses pembrolizumab as the defined antibody and US patent records as examples. No authorized sequence-alignment service was available, so M1 remains uncovered and the Sample stops short of a complete sequence-led screen.
Pembrolizumab · preliminary US evidence excerpt
An active sequence-defined anti-PD-1 claim family requires exact candidate-to-sequence comparison; a title hit for “anti-pembrolizumab antibodies” was screened out as a different product concept.
| Risk layer | Representative evidence | Screening meaning | Next action |
|---|---|---|---|
| Sequence / product | US8952136B2 claim 1; Patsnap status Active | Claim recites defined light- and heavy-chain CDRs plus PD-1 blocking function | Align authoritative candidate sequences and verify official status |
| Use / regimen | Large pembrolizumab combination and treatment set | Asset-name hits can concern another drug, indication, dose, or combination | Map only the planned indication and regimen |
| Process / formulation | Not completed in this excerpt | No non-mapping conclusion is available | Search host cell, production, purification, formulation, and route |
| False-positive control | US9995753B2 | Claims antibodies that bind pembrolizumab, not pembrolizumab itself | Retain as screened-out claim evidence |
Representative evidence is shown inside the artifact; verify decision-critical claims, current status, and jurisdiction-specific records before use.
Bring a defined scope and let the Skill build the evidence structure.
What the complete antibody FTO screen gives you
The Sample is intentionally partial because the sequence route was unavailable. A complete screen must connect the frozen candidate, every applicable search module, territorial family members, current claims, and planned acts.
Why antibody FTO needs several claim layers
Relevant claims can cover the antibody sequence, epitope, function, Fc, conjugation, formulation, manufacturing host, purification, dose, indication, biomarker, or combination. Shared target or high sequence similarity is a retrieval signal, not an infringement score.
What this partial run demonstrates
US8952136B2 claim 1 is sequence-defined and function-qualified. A responsible screen cannot map it from the name pembrolizumab alone. By contrast, US9995753B2 concerns antibodies that bind pembrolizumab, showing why titles must be resolved against claims.
Life-sciences decisions backed by linked evidence
Patsnap patent search, claims, family, bibliography, and simple legal status supported this triage. A material conclusion still needs an authorized sequence service, official-register verification, current claim versions, candidate records, and jurisdiction-qualified counsel.
Database foundationPatsnap connects drugs, targets, diseases, trials, literature, patents, biological sequences, and chemical structures in a linked life-sciences data foundation. Those relationships help preserve identity, provenance, development context, and competitive context across the analysis.
Patsnap OpenPatsnap Open makes selected data and tools available through APIs and MCP Servers for AI and enterprise workflows. Database coverage improves traceability, but experimental, clinical, regulatory, legal, and commercial validation remains necessary.
How the Skill completes the screen
Candidate, sequence, acts, markets, and cutoff.
Run sequence and M2–M9 technical modules.
Resolve families, members, claims, and status.
Compare every material limitation to evidence.
Prepare, install, and run
Provide authoritative VH/VL or chain sequences, numbering scheme, target, format, indication, regimen, formulation, process, jurisdictions, acts, and launch timing.
Screen pembrolizumab-related US patent risk by sequence/product, use/regimen, formulation, and manufacturing layers. Preserve claim versions and official-status gaps. If sequence alignment is unavailable, label M1 uncovered and return only an independently useful partial evidence pack.How to use the result
Use the claim-layer screen to decide which sequence, architecture, formulation, manufacturing, regimen, and treatment-use modules require deeper review and which candidate evidence must be completed first.
Before acting, verify the exact candidate version, authoritative sequences, planned acts, target-market members, current claims, status, ownership, and every material limitation mapping. An uncovered module or missing sequence comparison is an evidence gap—not a negative finding.
The report supports FTO prioritization and evidence planning. It does not establish claim non-infringement, clinical suitability, regulatory acceptability, or freedom to operate.
Connect the next verification step
Use a dedicated research connector when the remaining question needs current claims, family, status, sequence, or proceeding evidence.
Frequently asked questions
Can a drug name identify all blocking claims?
No. Claims may use sequences, functions, epitopes, formats, methods, doses, or combinations without using the commercial name.
Does an active database status prove enforceability?
No. Material members require official-register and prosecution review.
Can high sequence identity prove infringement?
No. It prioritizes claim review; every limitation and the applicable law still matter.
Disclosure: This article describes a Patsnap product and links to Patsnap Open. Skill output supports research and does not replace qualified technical, commercial, scientific, regulatory, or legal review.
